Has Yamin Sun, MD received payments from drug or device companies?

Yes. Drug and device makers reported $17,417 in general payments to Yamin Sun, MD across 802 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Yamin Sun, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Yamin Sun, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Yamin Sun, MD

Medical Oncology · Gainesville, GANPI 1801216080

Payments from drug & device makers

$17,417in general payments, 2019–2025

Across 802 payments — averaging $21.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$1K
AstraZeneca$1K
Merck$987
Bristol Myers Squibb$842
Exelixis Inc.$841
Johnson & Johnson$763
plus $11K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	67	$1,408
AstraZeneca(2 entities)	57	$1,041
Merck	44	$987
Bristol Myers Squibb	44	$842
Exelixis Inc.	21	$841
Johnson & Johnson(2 entities)	30	$763
E.r. Squibb & Sons, L.L.C.	39	$758
Genentech USA, Inc.	31	$710
Incyte Corporation	33	$701
Seagen Inc.	28	$687
Pfizer	40	$686
Daiichi Sankyo Inc.	35	$647
Bayer	16	$469
Eisai Inc.	20	$455
AbbVie	17	$433
GSK	20	$431
Takeda Pharmaceuticals U.S.A., Inc.	12	$407
Amgen	18	$358
Sanofi	16	$347
Jazz Pharmaceuticals Inc.	14	$332
Gilead(2 entities)	16	$310
Regeneron Healthcare Solutions, Inc.	13	$288
Pharmacyclics LLC, An Abbvie Company	12	$255
Lilly USA, LLC	13	$248
Rigel Pharmaceuticals, Inc.	11	$206
Tersera Therapeutics LLC	9	$196
Astellas Pharma US Inc	4	$181
Coherus Oncology, Inc.	9	$151
Puma Biotechnology, Inc.	7	$130
AVEO Pharmaceuticals, Inc.	5	$130
Servier Pharmaceuticals LLC	7	$116
Array Biopharma Inc	9	$112
Deciphera Pharmaceuticals Inc.	5	$112
EMD Serono, Inc.	5	$103
Pharmaessentia USA Corporation	4	$90
Boehringer Ingelheim	3	$88
Octapharma USA, Inc.	1	$86
Acrotech Biopharma Inc.	5	$81
Beigene USA, Inc.	4	$76
Morphosys, US Inc.	4	$74
Sumitomo Pharma America, Inc.	3	$68
Epizyme, Inc.	4	$66
Caris MPI, Inc.	3	$64
Beone Medicines USA, Inc.	3	$63
Acceleron Pharma, Inc.	3	$58
ADC Therapeutics America, Inc.	3	$57
Dova Pharmaceuticals	3	$55
Tempus AI, Inc	2	$52
Stemline Therapeutics Inc.	2	$50
Sun Pharmaceutical Industries Inc.	2	$50
Sobi, Inc	2	$44
Mirati Therapeutics, Inc.	2	$44
Taiho Oncology, Inc.	2	$40
Karyopharm Therapeutics Inc.	2	$39
Blueprint Medicines Corporation	2	$39
Myovant Sciences Inc.	2	$34
Ipsen Biopharmaceuticals, Inc	2	$33
Foundation Medicine, Inc.	2	$30
Azurity Pharmaceuticals, Inc.	1	$26
Tolmar, Inc.	1	$26

How this compares

$17,417 in reported general payments places this provider in the 45th percentile of 68 medical oncology providers in Georgia.

See all medical oncology providers in Georgia →

Medicare billing

Part B allowed, 2024

$1,226,734

Medicare patients

306

Services billed

72,268

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Gainesville

Charles NashGainesville$258K
Andrew JohnsonGainesville$252K
Richard LociceroGainesville$33K
Venumadhav KotlaGainesville$24K
Shravanti MacherlaGainesville$14K
Timothy CareyGainesville$14K
Devi SampatGainesville$13K
Jennifer AndersonGainesville$12K
Nancy SteadGainesville$2K
Suresh RamalingamAtlanta$10.5M

See the full list for Georgia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →